Source: Philadelphia Business Journal
Date: April 28, 2006
Summary:
Neuronyx Inc. will begin the first tests of its experimental adult stem-cell therapy treatment in human patients next month. The therapy involves injecting heart attack patients with stem cells harvested from adult bone marrow 30 days after their attack to preserve and potentially repair damaged heart tissue. In preclinical testing on animals the treatment showed the ability to regenerate damaged tissue.
